CAJ | 학술논문

IL-6在类风湿关节炎(RA)、幼年特发性全身性关节炎(sJIA)、Castleman病、系统性红斑狼疮(SLE)等多种风湿免疫性疾病发生、进展过程中均有过量表达,且发挥关键作用.Tolicizumab是第一个人源性的IL-6R抗体,通过特异性识别结合IL-6R而阻断IL-6生物学活性,发挥抑制上述疾病炎症反应的作用.大量研究结果证实,tocilizumab不仅能明显缓解RA的临床症状,而且能防止关节继续破坏.此外,tocilizumab在治疗全身性和关节型sJIA、Castleman病、SLE、克罗恩病等风湿免疫性疾病也获得了巨大的成功.
IL-6재류풍습관절염(RA)、유년특발성전신성관절염(sJIA)、Castleman병、계통성홍반랑창(SLE)등다충풍습면역성질병발생、진전과정중균유과량표체,차발휘관건작용.Tolicizumab시제일개인원성적IL-6R항체,통과특이성식별결합IL-6R이조단IL-6생물학활성,발휘억제상술질병염증반응적작용.대량연구결과증실,tocilizumab불부능명현완해RA적림상증상,이차능방지관절계속파배.차외,tocilizumab재치료전신성화관절형sJIA、Castleman병、SLE、극라은병등풍습면역성질병야획득료거대적성공.
Over-production of interleukin-6 (IL-6) plays an essential role in rheumatic autoimmune diseases such as rheumatoid arthritis (RA),juvenile idiopathic arthritis (JIA)and systemic lupus erythematosus (SLE).Tocilizumab,the first humanized anti-human IL-6 receptor antibody,can bind IL-6R by specific recognition and subsequently block the biological activity of IL-6.A large number of studies have demonstrated that tocilizumab was effective not only in improving clinical manifestation but also in preventing joint destruction of RA.In addition,A great successs has been made in the treatment of systemic and articular types of JIA,Castleman's disease,SLE,Crohu's disease,etc,by the application of tolicizubmab.